"Official medicines" is the best online drugstore.

World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system.

The meds you need, reliable and hassle free! Top products of top brands.

The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe!

(in-AM-rih-nohn)
Inocor
Class: Cardiovascular/positive inotropic

 Action Positive inotropic agent with vasodilator activity.

 Indications Short-term management of CHF in patients whose condition can be closely monitored and who have not responded adequately to digitalis, diuretics, or vasodilators.

 Contraindications Hypersensitivity to bisulfites.

 Route/Dosage

ADULTS: IV Initial dose: 0.75 mg/kg bolus slowly over 2 to 3 min. Maintenance: 5 to 10 mcg/kg/min; additional 0.75 mg/kg bolus may be given 30 min after initiating therapy, not to exceed total daily dose of 10 mg/kg.

 Interactions

None well documented.

INCOMPATIBILITIES: Dextrose-containing solutions: Chemical interaction occurs slowly over 24 hr when mixed directly. Furosemide: Do not inject furosemide into IV line containing inamrinone; immediate precipitate forms.

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Arrhythmia; hypotension. GI: Nausea; vomiting. HEMATOLOGIC Thrombocytopenia.

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Arrhythmias: Supraventricular and ventricular arrhythmias have occurred. Fluid balance: Vigorous diuretic therapy may cause inadequate response to inamrinone therapy; liberalization of fluids may be needed. CVP monitoring has been advocated. Hepatotoxicity: Dose may be reduced or drug may be discontinued if there are alterations in liver enzymes; if alterations occur with clinical symptoms, drug is discontinued. Post MI: Not recommended during acute phase. Severe aortic or pulmonic valvular disease: Not recommended. Sulfite sensitivity: May cause allergic-type reaction in susceptible patients. Thrombocytopenia: More common in patients on prolonged therapy.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

IV infusion

  • Administer as supplied or dilute in 0.5% or 0.9% saline to a concentration of 1 to 3 mg/mL.
  • Do not dilute in dextrose-containing solutions, although product may be injected into running dextrose infusion through Y-connector or directly into tubing. Do not infuse product and furosemide through same line.
  • Administer maintenance infusion 5 to 10 g/kg/min, preferably with infusion pump; adjust rate according to patient response.
  • Use diluted solutions within 24 hr.
  • Protect ampules from light.
  • Store at room temperature.

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Determine presence or history of asthma.
  • Review baseline ECG and assess ongoing cardiac monitoring. Notify physician of any arrhythmias.
  • Assess cardiac rate and rhythm throughout therapy.
  • Assess vital signs, especially BP and pulse, before and during therapy. Notify physician of excessive hypotension; slow or stop infusion.
  • Monitor I&O, including changes (increase or decrease) in output.
  • Monitor laboratory values for alterations in liver enzymes, renal function, platelets, and serum electrolytes. Notify physician of any changes.
  • Monitor for nausea and vomiting and for signs of hepatotoxicity.
OVERDOSAGE: SIGNS & SYMPTOMS
  Arrhythmias; excessive hypotension

 Patient/Family Education

  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Advise patient to notify physician of shortness of breath and increased chest pain.

Popularity: 1% [?]


If you're still unable to find appropriate information in the article, please use search form below